The first new drug imitated by esomeprazole of Laimei Pharmaceutical Co., Ltd. will be on the market soon

It is understood that digestive tract ulcer is a common digestive system disease, the incidence rate is 10%-12% in China, and some areas are as high as 28% Esomeprazole is a new generation of proton pump inhibitors (PPI) Compared with other PPIs, esomeprazole has the advantages of shorter course of treatment, more stable effect, more rapid and lasting effect, and has become the first-line drug for the treatment of peptic ulcer Yuan yuan, manager of Intellectual Property Department of Chongqing Laimei Pharmaceutical Co., Ltd., said that esomeprazole was first developed by AstraZeneca, an international pharmaceutical giant, and has been listed in major European and American countries since 2001 Before esomeprazole enteric coated capsules came into the market, only AstraZeneca imported products were available in the domestic market Through structural improvement, esomeprazole independently researched and developed by Laimei Pharmaceutical Co., Ltd obtained new drug certificate and production approval document in 2013, applied for two invention patents and went on the market recently, filling the gap in related fields in China At present, only the pharmaceutical industry of Laimei in China has the registration approval document of the drug It is understood that in the next few years, the annual sales of the drug is expected to reach 1 billion yuan The annual global sales of esomeprazole exceed 8 billion US dollars, and the domestic hospital terminal sales are 2.5 billion yuan